China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
IPO Year:
Exchange: AMEX
Website: chinapharmaholdings.com
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
DEF 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
PRE 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
HAIKOU, China, Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. It is a medical treatment device for dry eye disease under patent protection;The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registrat
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-302. The reverse stock split at a ratio of 1-for-5 shares was approved by the Company's Board of Directors through unanimous written consent on October 16, 2023 and adopted by the Company's stockholders
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China. According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic out
HAIKOU, China, Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has received the "Drug Supplementary Application Approval Notice" for its candesartan tablets by National Medical Products Administration of China (hereinafter referred to as NMPA"), indicating that the Company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs. The consistency evaluation of generic drugs evaluates approved generic drugs based on the p
HAIKOU, China, Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203. The reverse stock split at a ratio of 1-for-10 shares was approved by the Company's Board of Directors through unanimous written consent and the Company's stockholders through Annual Meeting for the fi
HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask"). On December 26, Hainan Medical Products Administration issued the Registration Certificate of N95 medical protective masks to Hainan Helpson Medical & Biotechnology Co., Ltd., providing a strong material guarantee for further optimizing the industrial layout, production capacity and reserves of epidemic prevention materials in Hainan Province. N95 Mask is a medical-level protection ma
HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread of the epidemic, people began to hoard many related drugs. The Chinese
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5
HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NYSE American") stating that the Company was not in compliance with a certain NYSE American continued listing standard relating to stockholders' equity, or Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer to have stockholders' equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency
HAIKOU, China, Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI, the ", Company", ))) today announced that on September 26, 2022, the Company received notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") informing it that the Company is not in compliance with certain NYSE American continued listing standards (the "Listing Standards"). The Deficiency Letter indicated that the Company's securities had been selling for a low price per share for a substantial period of time and, most recently, the average price of the Company's common stock had been below $0.20 on a 30-day average as of September 22, 2022. Pursuant to Section 1003(f)(v) of the NY
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
Gainers ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million. Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million. CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27. Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value
Gainers Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million. Entero Therapeutics (NASDAQ:ENTO) shares moved upwards by 8.69% to $2.25. The company's market cap stands at $6.1 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $34.5 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 5.92% to $0.29. Nutex Health (NASDAQ:NUTX) stock increased by 5.53% to $0.57. The market value of their outstanding shares is at $28.3 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 5.05%
Gainers Anitra (AMEX:AZTR) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million. TRACON Pharma (NASDAQ:TCON) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million. China Pharma Holdings, Inc. Common Stock (AM
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 12.83% to $0.33. BiomX (AMEX:PHGE) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. Virios Therapeutics (NASDAQ:VIRI) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. Accuray (NASDAQ:ARAY) stock increas
Gainers GT Biopharma (NASDAQ:GTBP) stock rose 153.2% to $7.9 during Monday's pre-market session. The company's market cap stands at $10.9 million. As per the press release, Q1 earnings came out 3 days ago. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares rose 42.9% to $0.47. As per the news, the Q1 earnings report came out 3 days ago. Kintara Therapeutics (NASDAQ:KTRA) shares rose 28.95% to $0.18. The market value of their outstanding shares is at $7.1 million. The company's, Q3 earnings came out 4 days ago. PTC Therapeutics (NASDAQ:PTCT) stock rose 26.9% to $42.0. The market value of their outstanding shares is at $3.2 billion. China SXT Pharmaceuticals (NASDAQ:SXTC) stock i
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock rose 10.15% to $0.33. Imunon (NASDAQ:IMNN) shares increased by 7.63% to $1.55. The market value of their outstanding shares is at $14.5 million. Accolade (NASDAQ:ACCD) shares increased by 5.83% to $8.35. The market value of their outstanding shares is at $646.3 million. The company's, Q4 earnings came out yesterday. Prime Medicine (NASDAQ:PRME) shares increased by 5.53% to $4.67. The market value of their outstanding shares is at $560.1 million. ASLAN Pharma (NASDAQ:
Gainers Acrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. Amarin Corp (NASDAQ:AMRN) stock moved upwards by 8.12% to $0.95. The company's market cap stands at $381.2 million. Universe Pharmaceuticals (NASDAQ:UPC) stock rose 7.47% to $2.3. The market value of their outstanding shares is at $8.3 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 7.14% to $0.34. Telesis Bio (NASDAQ:TBIO) shares moved upwards by 7.12% to $0.34. The company's market cap stands at $10.3 million. Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 6.
Gainers Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. Galera Therapeutics (NASDAQ:GRTX) stock increased by 9.13% to $0.2. The market value of their outstanding shares is at $10.9 million. Innovative Eyewear (NASDAQ:LUCY) shares increased by 8.54% to $0.26. The company's market cap stands at $3.4 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock moved upwards by 6.7% to $0.34. Calidi Biotherapeutics (AMEX:CLDI) shares increased by 6.17% to $0.17. The market value of their outstanding shares is at $8.4 million. Adaptimmune Therapeutics (NASDAQ:ADAP) shares increased
Gainers Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, the Q4 earnings report came out 2 days ago. Sunshine Biopharma (NASDAQ:SBFM) shares rose 46.11% to $0.09. The company's market cap stands at $8.7 million. Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 44.94% to $1.0. The market value of their outstanding shares is at $35.7 million. Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 27.77% to $1.38. The market value of their outstanding shares is at $37.9 million. Innate Pharma (NASDAQ:IPHA) shares moved upwards by 18.05% to $3.4.
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)